1. Home
  2. CYCN vs JAGX Comparison

CYCN vs JAGX Comparison

Compare CYCN & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cyclerion Therapeutics Inc.

CYCN

Cyclerion Therapeutics Inc.

HOLD

Current Price

$3.19

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$3.16

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYCN
JAGX
Founded
2018
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
5.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
CYCN
JAGX
Price
$3.19
$3.16
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
63.2K
131.3K
Earning Date
05-08-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.42
EPS
N/A
N/A
Revenue
N/A
$11,511,000.00
Revenue This Year
N/A
$61.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.22
52 Week High
$8.48
$8.00

Technical Indicators

Market Signals
Indicator
CYCN
JAGX
Relative Strength Index (RSI) 55.78 54.52
Support Level $2.88 $1.74
Resistance Level $3.50 $4.13
Average True Range (ATR) 0.16 0.51
MACD -0.01 -0.15
Stochastic Oscillator 73.81 29.32

Price Performance

Historical Comparison
CYCN
JAGX

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: